Odronextamab(Odronextamab) - 药物靶点：CD20 x CD3_在研适应症：复发性弥漫性大B细胞淋巴瘤，难治性弥漫性大 B 细胞淋巴瘤，复发性滤泡性淋巴瘤_专利_临床

概要

基本信息

药物类型

双特异性T细胞结合器

别名

CD20xCD3 bispecific antibody、Odronextamab (USAN)、REGN-1979

+ [4]

靶点

CD20 x CD3

作用机制

CD20抑制剂(B淋巴细胞抗原CD20抑制剂)、CD3刺激剂(T细胞表面糖蛋白CD3复合体刺激剂)、ADCC(抗体依赖的细胞毒作用)

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病+ [1]

在研适应症

复发性弥漫性大B细胞淋巴瘤难治性弥漫性大 B 细胞淋巴瘤复发性滤泡性淋巴瘤+ [15]

非在研适应症-

原研机构

Regeneron Pharmaceuticals, Inc.

在研机构

再鼎医药（上海）有限公司

Regeneron Pharmaceuticals, Inc.Regeneron Ireland DAC

非在研机构

Catalent Indiana LLC

最高研发阶段批准上市

首次获批日期

欧盟 (2024-08-22),

复发性弥漫性大B细胞淋巴瘤难治性弥漫性大 B 细胞淋巴瘤复发性滤泡性淋巴瘤+ [1]

最高研发阶段(中国)临床3期

特殊审评优先审评 (美国)、快速通道 (美国)、孤儿药 (欧盟)

登录后查看时间轴

结构/序列

Sequence Code 9960254L

来源: *****

Sequence Code 9960260H

来源: *****

Sequence Code 9960266H

来源: *****

关联

14

项与 Odronextamab 相关的临床试验

NCT06735664

/ Not yet recruiting临床1期IIT

A Phase I Study of Covalent BTK Inhibitor Zanubrutinib in Combination With a CD3-CD20 Bispecific Antibody Odronextamab in Patients With Richter's Transformation

This phase I trial tests the safety and side effects of zanubrutinib in combination with odronextamab and how well it works in treating patients with Richter's transformation. Zanubrutinib, a tyrosine kinase inhibitor, blocks a protein called Bruton tyrosine kinase (BTK), which may help keep cancer cells from growing. Odronextamab is a bispecific monoclonal antibody that can bind to two different antigens at the same time. Odronextamab binds to CD20 found on B-cells (a type of white blood cell) and on many B-cell cancers and to CD3 on T-cells (also a type of white blood cell) and may interfere with the ability of cancer cells to grow and spread. Giving zanubrutinib in combination with odronextamab may be safe, tolerable and/or effective in treating patients with Richter's transformation.

开始日期2025-08-14

申办/合作机构

City of Hope National Medical Center

[+1]

NCT06784726

/ Not yet recruiting临床2期IIT

Odronextamab for Relapsed/Refractory Large B-cell Lymphomas Before Definitive Lymphoma-Directed Therapies

This phase II trial tests the effectiveness of odronextamab given before chimeric antigen receptor T (CAR-T) cell therapy (bridging therapy) in patients with large B-cell lymphomas that have come back after a period of improvement (relapsed) or that have not responded to previous treatment (refractory). Odronextamab is a bispecific antibody that can bind to two different antigens at the same time. Odronextamab binds to CD3, a T-cell surface antigen, and CD20 (a tumor-associated antigen that is expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell cancers) and may interfere with the ability of cancer cells to grow and spread. Bridging therapy has been used to maintain disease control and to increase the chance of successful receipt of CAR-T cell therapy. However, bridging therapy is typically given after leukapheresis, which does not help prevent disease progression between the decision for CAR-T cell therapy and leukapheresis. Giving odronextamab as bridging therapy before leukapheresis may delay disease progression to allow leukapheresis and increase the likelihood of successful CAR-T cell therapy in patients with relapsed or refractory large B-cell lymphomas.

开始日期2025-04-01

申办/合作机构

University of Washington

[+1]

NCT05991388

/ Recruiting临床2/3期IIT

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

The Glo-BNHL trial is trying to find better medicines for children and young people with B-cell non-Hodgkin Lymphoma (B-NHL) that does not go away (refractory B-NHL) or does but comes back again (relapsed B-NHL). B-NHL is a type of cancer that develops inside or outside of lymph nodes (glands) and organs such as the liver or spleen. Examples of B-NHL are Burkitt Lymphoma and Diffuse Large B Cell Lymphoma, which may be other names used to describe this type of cancer. It is very difficult to cure relapsed or refractory B-NHL. The medicines used now are very powerful with many side effects and only cure around 30 in every 100 children treated. It is very important that investigators quickly find better medicines for these children and young people.
The Glo-BNHL trial will include three groups of children and young people, each given a new medicine (either alone or with chemotherapy). The investigators are looking to make sure the new medicines are safe and that they work to treat the cancer. If the medicine in one group does not work for a child in the trial, then they may be able to join a different group to have another new medicine.
Experts from around the world will carefully pick the medicines most likely to be helpful to be part of the trial. If one of the new medicines seems not to be working as well as hoped then the investigators will take it out of the trial as soon as possible. This will let other new medicines be added to the trial and tested. If a medicine does seem to be working well, then it will continue in the trial to make sure it really is the most useful medicine available.
Children from around the world will be invited to take part in the trial. The investigators will then check on them for at least two years after they finish the trial treatment to look for possible side effects of the new medicine.

开始日期2024-05-02

申办/合作机构

University of Birmingham

[+3]

100 项与 Odronextamab 相关的临床结果

登录后查看更多信息

100 项与 Odronextamab 相关的转化医学

登录后查看更多信息

100 项与 Odronextamab 相关的专利（医药）

登录后查看更多信息

47

项与 Odronextamab 相关的文献（医药）

2025-12-31·mAbs

Antibodies to watch in 2025

Review

作者: Kapoor, Vaishali ; Kaplon, Hélène ; Crescioli, Silvia ; Visweswaraiah, Jyothsna ; Reichert, Janice M. ; Wang, Lin

The commercial development of antibody therapeutics is a global enterprise involving thousands of biopharmaceutical firms and supporting service organizations. To date, their combined efforts have resulted in over 200 marketed antibody therapeutics and a pipeline of nearly 1,400 investigational product candidates that are undergoing evaluation in clinical studies as treatments for a wide variety of diseases. Here, we discuss key events in antibody therapeutics development that occurred during 2024 and forecast key events related to the late-stage clinical pipeline that may occur in 2025. In particular, we report on 21 antibody therapeutics granted a first approval in at least one country or region during 2024, including bispecific antibodies tarlatamab (IMDELLTRA®), zanidatamab (Ziihera®), zenocutuzumab (BIZENGRI®), odronextamab (Ordspono®), ivonescimab (®), and antibody-drug conjugate (ADC) sacituzumab tirumotecan (®). We also discuss 30 investigational antibody therapeutics for which marketing applications were undergoing review by at least one regulatory agency, as of our last update on December 9, 2024, including ADCs datopotamab deruxtecan, telisotuzumab vedotin, patritumab deruxtecan, trastuzumab botidotin, becotatug vedotin, and trastuzumab rezetecan. Of 178 antibody therapeutics we include in the late-stage pipeline, we summarize key data for 18 for which marketing applications may be submitted by the end of 2025, such as bi- or multispecific antibodies denecimig, sonelokimab, erfonrilimab, and anbenitamab. Key trends in the development and approval of antibody formats such as bispecifics and ADCs, as well as clinical-phase transition and global approval success rates for these antibody formats, are reported.

2024-12-31·mAbs

Antibodies to watch in 2024

Article

作者: Crescioli, Silvia ; Kaplon, Hélène ; Wang, Lin ; Reichert, Janice M. ; Visweswaraiah, Jyothsna ; Chenoweth, Alicia

The 'Antibodies to Watch' article series provides an annual summary of commercially sponsored monoclonal antibody therapeutics currently in late-stage clinical development, regulatory review, and those recently granted a first approval in any country. In this installment, we discuss key details for 16 antibody therapeutics granted a first approval in 2023, as of November 17 (lecanemab (Leqembi), rozanolixizumab (RYSTIGGO), pozelimab (VEOPOZ), mirikizumab (Omvoh), talquetamab (Talvey), elranatamab (Elrexfio), epcoritamab (EPKINLY), glofitamab (COLUMVI), retifanlimab (Zynyz), concizumab (Alhemo), lebrikizumab (EBGLYSS), tafolecimab (SINTBILO), narlumosbart (Jinlitai), zuberitamab (Enrexib), adebrelimab (Arelili), and divozilimab (Ivlizi)). We briefly review 26 product candidates for which marketing applications are under consideration in at least one country or region, and 23 investigational antibody therapeutics that are forecast to enter regulatory review by the end of 2024 based on company disclosures. These nearly 50 product candidates include numerous innovative bispecific antibodies, such as odronextamab, ivonescimab, linvoseltamab, zenocutuzumab, and erfonrilimab, and antibody-drug conjugates, such as trastuzumab botidotin, patritumab deruxtecan, datopotamab deruxtecan, and MRG002, as well as a mixture of two immunocytokines (bifikafusp alfa and onfekafusp alfa). We also discuss clinical phase transition and overall approval success rates for antibody therapeutics, which are crucial to the biopharmaceutical industry because these rates inform decisions about resource allocation. Our analyses indicate that these molecules have approval success rates in the range of 14-32%, with higher rates associated with antibodies developed for non-cancer indications. Overall, our data suggest that antibody therapeutic development efforts by the biopharmaceutical industry are robust and increasingly successful.

2024-12-01·Clinical Lymphoma Myeloma & Leukemia

SOHO State of the Art Updates and Next Questions | Current Evidence and Future Directions for Bispecific Antibodies in Large B-Cell Lymphoma

Review

作者: Bennett, Rory ; Dickinson, Michael

The CD20xCD3 bispecific antibodies (bsAb) are "off-the-shelf" T-cell re-directing therapies that demonstrate remarkable single-agent clinical activity in B-cell lymphomas. Two agents, epcoritamab (epcor) and glofitamab (glofit) have recent global approvals for patients with relapsed/refractory DLBCL (RR DLBCL) following 2 prior treatment lines. Both agents demonstrate activity in patients with prior exposure to chimeric antigen receptor T-cell (CAR-T) treatment. As multiyear follow-up data become available, it is clear that the majority of patients achieving complete remissions do not relapse and that outcomes are similar between epcor and glofit. CD20xCD3 bsAb have a safety profile that reflect their mechanism of action, with cytokine release syndrome (CRS) the key management issue. Neurotoxicity is far less common than observed with CD19-directed CAR-T. BsAbs are attractive, rapidly available, treatment options for patients with RR DLBCL, without the practical and financial challenges seen with autologous CAR-T therapies. Recent data also demonstrate the feasibility and potential efficacy of bsAb in combination with chemoimmunotherapy with large randomized trials evaluating bsAb-chemotherapy combinations underway. There are open questions about the future role of bsAB for LBCL, the optimal duration of therapy, optimal CRS risk mitigation strategies, and potential resistance mechanisms. In this review we seek to describe the current evidence for bsAb in LBCL, and offer opinion regarding these open questions.

180

项与 Odronextamab 相关的新闻（医药）

2025-01-20

·药明康德

超5亿美元！又一款双特异性抗体达成授权，临床试验已启动

▎药明康德内容团队编辑诺诚健华（InnoCare Pharma）和康诺亚（KeyMed Biosciences）今天宣布，两家公司与Prolium Bioscience达成独家许可协议，将共同开发和商业化双特异性抗体ICP-B02（CM355）用于治疗癌症患者。 ICP-B02是由诺诚健华和康诺亚联合开发的CD20×CD3靶向双特异性抗体。该疗法可与肿瘤细胞上的CD20和T细胞上的CD3结合，通过T细胞介导的细胞毒性（TDCC）重定向和激活T细胞来消灭肿瘤细胞，这在肿瘤和非肿瘤领域具有潜在的治疗应用价值。ICP-B02目前正在中国进行1/2期临床试验，以评估该疗法在复发/难治性非霍奇金淋巴瘤（NHL）中的安全性、耐受性、药代动力学（PK）和初步抗肿瘤活性。分析显示，该疗法的静脉（IV）和皮下（SC）制剂均取得了积极的早期结果，特别是针对滤泡性淋巴瘤（FL）和弥漫性大B细胞淋巴瘤（DLBCL）患者。基于ICP-B02单药令人鼓舞的结果，公司计划对ICP-B02与其他免疫化疗组合进行剂量扩展研究，用以早期治疗NHL患者。目前联合疗法的IND已获批准。根据协议条款，Prolium将拥有在全球非肿瘤领域以及亚洲以外地区肿瘤领域的开发、注册、生产和商业化ICP-B02的独家权利。诺诚健华和康诺亚则将获得总计高达5.2亿美元的付款，包括预付款和短期付款以及实现某些临床、监管和商业里程碑后可获得的其他款项。值得一提的是，2025年初甫完成1.2亿美元A轮融资的Ouro Medicines，其进展最快的候选疗法OM336也是在近期从康诺亚授权获得。这是一款靶向B细胞成熟抗原（BCMA）的双特异性T细胞接合器。Ouro Medicines计划于2025年启动其首个1期临床试验，用以治疗B细胞介导免疫疾病患者。此外，同样于今年初完成1.8亿美元A轮融资的Timberlyne Therapeutics，其旗下潜在“best-in-class”的CD38靶向单克隆抗体CM313最初也是由康诺亚所开发。最近发表于《新英格兰医学杂志》的结果显示，CM313在治疗难治性免疫性血小板减少症患者的一项临床试验中，让95%的患者达到临床主要终点。 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料： [1] InnoCare and KeyMed Jointly Announce the License Agreement with Prolium for CD20xCD3 Bispecific Antibody ICP-B02. Retrieved January 20, 2025 from https://www.businesswire.com/news/home/20250120534760/en/InnoCare-and-KeyMed-Jointly-Announce-the-License-Agreement-with-Prolium-for-CD20xCD3-Bispecific-Antibody-ICP-B02 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

引进/卖出临床申请临床1期免疫疗法

2025-01-20

·PipelineReview

InnoCare and KeyMed Jointly Announce the License Agreement with Prolium for CD20xCD3 Bispecific Antibody ICP-B02

BEIJING, China I January 20, 2025 I InnoCare Pharma (HKEX: 09969; SSE: 688428) and KeyMed Biosciences (HKEX: 02162) today announced that the two companies, together with their joint venture, have jointly entered into an exclusive license agreement with Prolium Bioscience (Prolium) for the development and commercialization of ICP-B02 (CM355), a CD20xCD3 bispecific antibody. ICP-B02 binds to CD20 on the tumor cells and CD3 on the T cells, redirects and activates T cells to eradicate tumor cells through T-cell Directed Cellular Cytotoxicity (TDCC), which has demonstrated strong potential in both oncology and non-oncology fields. Under the terms of the agreement, Prolium will have the exclusive right to develop, register, manufacture and commercialize ICP-B02 in the non-oncology field globally and in the oncology field in ex-Asia regions. InnoCare and KeyMed will receive aggregate payments of up to $520 million, including upfront and near-term payments and other payments subject to the achievement of certain clinical, regulatory and commercial milestones, as well as a minority equity stake in Prolium. InnoCare and KeyMed are also eligible to receive tiered royalties on future net sales of any product resulting from the collaboration. Prolium is a Delaware company funded and backed by RTW Investments, LP, a New York-based, global, full life-cycle investment firm that focuses on identifying transformational and disruptive innovations across the biopharmaceutical and medical technologies sectors. About ICP-B02 (CM355) ICP-B02 is a CD20×CD3 bispecific antibody jointly developed by InnoCare and KeyMed. A Phase I/II clinical trial in China is ongoing to assess the safety, tolerability, PK and the preliminary anti-tumor activity of ICP-B02 in relapsed / refractory Non-Hodgkin lymphoma (NHL). The study has shown promising early results in both intravenous (IV) and subcutaneous (SC) formulations, particularly in patients with follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Based on the encouraging results of ICP-B02 single agent, a dose expansion study of ICP-B02 in combination with other immunochemotherapies is planned to target earlier lines of treatment for NHL patients. The IND for the combination therapies has been approved. About InnoCare InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and United States. About Keymed Biosciences Keymed Biosciences Inc. (HKEX: 02162) focuses on the urgent unmet clinical needs, and is committed to providing high-quality, affordable, innovative therapies for patients in China and overseas. Keymed was founded by medical and scientific experts who have strong experience in the transformation of scientific and technological achievements to commercialization at home and abroad. SOURCE: InnoCare

引进/卖出免疫疗法临床申请

2025-01-20

·抗体密码

5.2亿美元，又一款CD20xCD3双抗出海！

2025年1月20日，康诺亚和诺诚健华联合宣布，两家公司及其双方的合资公司共同与Prolium Bioscience（以下简称Prolium）达成许可合作，授权Prolium开发和商业化CD20×CD3双特异性抗体CM355（ICP-B02）。根据协议条款，Prolium将获得在全球非肿瘤领域以及亚洲以外肿瘤领域开发、注册、生产和商业化CM355（ICP-B02）的权利。康诺亚和诺诚健华将获得最高5.2亿美元的总付款，包括首付款和近期付款，以及其他达成临床开发、注册和商业化里程碑的额外付款，并且双方将获得Prolium的少数股权。同时，康诺亚和诺诚健华还将获得未来产品净销售额的分层特许权使用费。 CD20/CD3 TCE在双抗领域的开发无疑是自免方向，根据之前康诺亚披露，该抗体利用康诺亚nTCE平台构建，其具有较大的肿瘤细胞杀伤活性，同时具有较低的细胞因子释放。在临床前研究中，CM355相较于其主要竞品（REGN1979及mosunetuzumab），表现出较強的T細胞依賴性細胞毒性(TDCC)活性，且释放相当或较少的細胞因子，如下圖所示。在临床中，目前该双抗正在中国开展 I/II 期临床试验，旨在评估CM355(ICP-B02)在复发/难治性非霍奇金淋巴瘤(NHL)患者中的安全性、耐受性、药代动力学(PK)以及抗肿瘤活性。研究显示，CM355(ICP-B02)的静脉输注(IV)制剂和皮下注射(SC)制剂在滤泡性淋巴瘤(FL)和弥漫性大B细胞淋巴瘤(DLBCL)患者中展示了初步的良好疗效。自去年下半年以来，TCE在自免领域交易不断，目前已经多个靶向B细胞的TCE双抗成功出海，这些抗体总体上有一些共性：1）基本上都已经进入临床；2）初步的临床数据具有较好的疗效；3）具有较好的安全性。目前这些TCE双抗的靶点多集中在CD19，CD20，BCMA，但是除这些靶点外，还有一些其它的靶点可用于自免TCE的开发，而且相关TCE联合或者组合成多抗也有很大的机会。我们已经建立抗体密码读者交流群，有兴趣的可以扫描下方二维码添加微信进群，请主动备注姓名-公司-职位（高校-专业），非诚勿扰！往期精彩回顾抗体密码文章合集双特异抗体平台靶点相关双特异抗体作用机制综述，行业概览抗体筛选技术相关公司技术汇总医药资讯因为你的分享、点赞、在看我足足的精气神儿！声明本公众号所发表文章以宣传知识为目的，因此不构成投资，病人用药等建议。如果文章侵您的权益及时联系小编进行删除！欢迎扫码交流/咨询/合作= 参考文献：康诺亚官网

引进/卖出临床1期

100 项与 Odronextamab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11534	-	-	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
复发性弥漫性大B细胞淋巴瘤	欧盟	Regeneron Ireland DAC	2024-08-22
复发性弥漫性大B细胞淋巴瘤	冰岛	Regeneron Ireland DAC	2024-08-22
复发性弥漫性大B细胞淋巴瘤	列支敦士登	Regeneron Ireland DAC	2024-08-22
复发性弥漫性大B细胞淋巴瘤	挪威	Regeneron Ireland DAC	2024-08-22
难治性弥漫性大 B 细胞淋巴瘤	欧盟	Regeneron Ireland DAC	2024-08-22
难治性弥漫性大 B 细胞淋巴瘤	冰岛	Regeneron Ireland DAC	2024-08-22
难治性弥漫性大 B 细胞淋巴瘤	列支敦士登	Regeneron Ireland DAC	2024-08-22
难治性弥漫性大 B 细胞淋巴瘤	挪威	Regeneron Ireland DAC	2024-08-22
复发性滤泡性淋巴瘤	欧盟	Regeneron Ireland DAC	2024-08-22
复发性滤泡性淋巴瘤	冰岛	Regeneron Ireland DAC	2024-08-22
复发性滤泡性淋巴瘤	列支敦士登	Regeneron Ireland DAC	2024-08-22
复发性滤泡性淋巴瘤	挪威	Regeneron Ireland DAC	2024-08-22
难治性滤泡性淋巴瘤	欧盟	Regeneron Ireland DAC	2024-08-22
难治性滤泡性淋巴瘤	冰岛	Regeneron Ireland DAC	2024-08-22
难治性滤泡性淋巴瘤	列支敦士登	Regeneron Ireland DAC	2024-08-22
难治性滤泡性淋巴瘤	挪威	Regeneron Ireland DAC	2024-08-22

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
侵袭性 B 细胞非霍奇金淋巴瘤	临床3期	澳大利亚	Regeneron Pharmaceuticals, Inc.	2024-02-15
侵袭性 B 细胞非霍奇金淋巴瘤	临床3期	意大利	Regeneron Pharmaceuticals, Inc.	2024-02-15
侵袭性 B 细胞非霍奇金淋巴瘤	临床3期	马来西亚	Regeneron Pharmaceuticals, Inc.	2024-02-15
侵袭性 B 细胞非霍奇金淋巴瘤	临床3期	荷兰	Regeneron Pharmaceuticals, Inc.	2024-02-15
侵袭性 B 细胞非霍奇金淋巴瘤	临床3期	新加坡	Regeneron Pharmaceuticals, Inc.	2024-02-15
侵袭性 B 细胞非霍奇金淋巴瘤	临床3期	韩国	Regeneron Pharmaceuticals, Inc.	2024-02-15
侵袭性 B 细胞非霍奇金淋巴瘤	临床3期	西班牙	Regeneron Pharmaceuticals, Inc.	2024-02-15
侵袭性 B 细胞非霍奇金淋巴瘤	临床3期	中国台湾	Regeneron Pharmaceuticals, Inc.	2024-02-15
侵袭性 B 细胞非霍奇金淋巴瘤	临床3期	泰国	Regeneron Pharmaceuticals, Inc.	2024-02-15
侵袭性 B 细胞非霍奇金淋巴瘤	临床3期	土耳其	Regeneron Pharmaceuticals, Inc.	2024-02-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03888105 (ELM-2, EHA 12024 \| EHA 22024) 人工标引	临床2期	滤泡性淋巴瘤 CD20 \| CD3	128	Odronextamab	簾廠範網餘衊範築壓構(網範艱襯繭淵壓構蓋鑰) = 獵艱鑰構淵鹹願糧鏇觸範範齋觸鹽衊糧憲遞廠 (齋鑰衊憲窪選艱積範憲 ) 更多	积极	2024-05-14
NCT02290951 (ELM-1, EHA 12024 \| EHA 22024) 人工标引	临床1期	弥漫性大B细胞淋巴瘤	44	Odronextamab	遞觸簾鑰衊膚網廠鏇齋(鏇淵觸齋夢鹽壓廠窪鹽) = 憲獵鑰鏇積艱襯鏇淵構膚鏇淵構觸壓繭膚選網 (壓網夢獵鹹憲襯遞餘襯 ) 更多	积极	2024-05-14
NCT03888105 \| NCT02290951 (ELM-2, EHA2024) 人工标引	临床1/2期	滤泡性淋巴瘤 \| 弥漫性大B细胞淋巴瘤 CD20 \| CD3 \| cytokines	507	Odronextamab 80 mg QW	範觸糧夢製淵築繭鏇願(糧製製遞廠願齋製繭鬱) = 選構鑰廠簾範憲廠鑰醖築網壓積願糧廠憲獵襯 (鹹網範遞繭鏇網壓窪範 )	积极	2024-05-14
NCT03888105 \| NCT02290951 (ELM-2, EHA2024) 人工标引	临床1/2期	滤泡性淋巴瘤 \| 弥漫性大B细胞淋巴瘤 CD20 \| CD3 \| cytokines	507	Odronextamab 160 mg QW	範觸糧夢製淵築繭鏇願(糧製製遞廠願齋製繭鬱) = 繭顧鏇襯衊繭網顧糧夢築網壓積願糧廠憲獵襯 (鹹網範遞繭鏇網壓窪範 )	积极	2024-05-14
NCT03888105 (ELM-2, EHA2024)	临床2期	滤泡性淋巴瘤 \| 难治性滤泡性淋巴瘤 \| 弥漫性大B细胞淋巴瘤 ... ctDNA \| MRD \| MYC/BCL2/BCL6 rearrangement ... 更多	-	Odronextamab 80 mg (FL)/160 mg (DLBCL) weekly in C2-4, then 160 mg (FL)/320 mg (DLBCL) every 2 weeks	壓憲選齋鹽衊憲膚繭遞(艱艱衊繭窪網鏇築廠艱) = 壓願膚顧蓋鹽顧選築艱鬱顧憲憲積壓鏇餘衊餘 (夢構膚齋蓋廠願憲構淵 )	积极	2024-05-14
NCT03888105 (ELM-2, EHA2024)	临床2期		-	Placebo	壓憲選齋鹽衊憲膚繭遞(艱艱衊繭窪網鏇築廠艱) = 選憲簾艱餘遞蓋鑰築齋鬱顧憲憲積壓鏇餘衊餘 (夢構膚齋蓋廠願憲構淵 )	积极	2024-05-14
NEWS 人工标引	N/A	难治性滤泡性淋巴瘤 \| 复发性弥漫性大B细胞淋巴瘤	-	Odronextamab (R/R FL)	鹹壓網獵顧簾選製製願(網鏇繭獵齋夢簾鹽繭淵) = 廠齋鹽選繭築鏇蓋範構餘積蓋蓋衊膚淵鏇糧夢 (製鏇壓壓構淵淵觸積繭 ) 更多	积极	2024-01-08
NEWS 人工标引	N/A	难治性滤泡性淋巴瘤 \| 复发性弥漫性大B细胞淋巴瘤	-	Odronextamab (R/R DLBCL (CAR-T naïve))	鹹壓網獵顧簾選製製願(網鏇繭獵齋夢簾鹽繭淵) = 膚窪窪構築網蓋繭獵衊餘積蓋蓋衊膚淵鏇糧夢 (製鏇壓壓構淵淵觸積繭 ) 更多	积极	2024-01-08
NCT03888105 (ELM-2, ASH2023)	临床2期	弥漫性大B细胞淋巴瘤	141	Odronextamab	觸繭餘廠襯醖膚網選構(遞鑰範觸艱鏇窪膚獵願) = 鑰鹹範獵蓋壓衊構艱壓膚範蓋選鏇壓淵網糧積 (廠蓋鹹鹹遞艱糧願觸網 ) 更多	积极	2023-12-10
NCT03888105 (ELM-2, ASH2023)	临床2期	难治性滤泡性淋巴瘤 \| 弥漫性大B细胞淋巴瘤	-	Odronextamab	鬱鹹築膚鑰艱齋壓觸齋(願簾製遞積構蓋襯襯獵) = 鑰窪製顧簾齋鏇鏇膚醖壓選鑰鬱構夢蓋鹽鹹廠 (築鏇獵願餘築窪築積餘 )	-	2023-12-10
NCT03888105 (ELM-2, ASH2023)	临床2期	难治性滤泡性淋巴瘤	140	Odronextamab	鏇窪膚鑰淵鑰觸淵膚網(蓋衊艱膚醖鏇醖夢糧襯) = 鬱壓鬱鑰鬱膚蓋構憲網衊襯鹽觸簾膚醖膚鹹觸 (築繭鬱艱網餘淵膚壓顧 ) 更多	-	2023-12-10
NCT02651662 (ASH2023)	临床1期	侵袭性 B 细胞非霍奇金淋巴瘤	60	Odronextamab	膚壓簾遞範範積衊簾齋(鏇淵鹽獵夢選餘鏇壓壓) = 餘鹽餘夢餘襯願艱鹽夢憲窪艱衊憲淵廠範網襯 (鹹獵衊顧糧壓廠觸鏇遞 ) 更多	-	2023-12-10
NCT03888105 (ELM-2, ICML2023)	临床2期	复发性 3a 级滤泡性淋巴瘤 CD20 \| CD3	131	Odronextamab 1/20 regimen	齋鑰壓觸鹽膚衊醖製鏇(淵鹽壓鑰膚窪構鑰獵鬱) = 夢鬱範簾範窪膚鬱鹽襯鬱製觸範襯膚簾網襯鑰 (憲衊願壓憲齋積醖簾獵 ) 更多	积极	2023-06-09